Management of antineutrophil cytoplasmic antibody associated vasculitis

Nikiphorou, Elena and Mukhtyar, Chetan ORCID: (2011) Management of antineutrophil cytoplasmic antibody associated vasculitis. Current Immunology Reviews, 7 (4). pp. 429-434. ISSN 1573-3955

Full text not available from this repository.


Wegener's granulomatosis (WG), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS) are grouped together under the term 'Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis' (AAV). Recently, the British Society for Rheumatology and the European League Against Rheumatism have individually published recommendations on the management of AAV. This paper reviews the two recommendations, and the recent advances in the management of AAV. Pattern recognition and clinical suspicion remains the cornerstone for an early diagnosis. The combination of cyclophosphamide and glucocorticoid is the standard of therapy for remission induction. Patients with less severe disease can be treated effectively with less toxic therapies. There is almost no reason to routinely continue using cyclophosphamide beyond 6 months. Long-term remission maintenance is possible with a variety of immunomodulating agents. With increasing survival, the recognition and management of complications like cardiovascular disease, renal failure, malignancy requires long-term follow up and regular screening.

Item Type: Article
Uncontrolled Keywords: antineutrophil cytoplasmic antibody,chrug-strauss syndrome,microscopic polyangiitis,remission,vasculitis,wegener's granulomatosis,immunology and allergy,immunology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2723
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 05 Jun 2020 00:02
Last Modified: 22 Oct 2022 06:16
DOI: 10.2174/157339511797535117

Actions (login required)

View Item View Item